CAdd image
Cagrilintide
Weight LossSingleA long-acting amylin analog studied as a monotherapy and in combination with semaglutide (CagriSema) for weight management.
Half-life
168 h
Common dose
160 – 2400 mcg
Dosing frequency
Weekly
Administration
Subcutaneous
How it works
Cagrilintide is a synthetic analog of the pancreatic hormone amylin, which slows gastric emptying and promotes satiety. It complements GLP-1 agonist mechanisms with non-overlapping pathways.
Protocol notes
Trial dosing typically titrates from 0.16 mg weekly up to 2.4 mg weekly over several months. Often combined 1:1 with semaglutide.
Reported side effects
Nausea, decreased appetite, injection-site reactions, fatigue, occasional vomiting.